PortalPublikationenTesting G-CSF responsiveness predicts the individual suscept...

Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.

Standard

Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. / Straka, Christian; Sandherr, Michael; Salwender, Hans; Wandt, Hannes; Metzner, Bernd; Hübel, Kai; Silling, Gerda; Hentrich, Marcus; Franke, Daniel; Schwerdtfeger, Rainer; Freund, Mathias; Sezer, Orhan; Giagounidis, Alexander; Ehninger, Gerhard; Grimminger, Wolfgang; Engert, Andreas; Schlimok, Günter; Scheid, Christof; Hellmann, Peter; Heinisch, Harald; Einsele, Hermann; Hinke, Axel; Emmerich, Bertold.

in: BLOOD, Jahrgang 117, Nr. 7, 7, 2011, S. 2121-2128.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Straka, C, Sandherr, M, Salwender, H, Wandt, H, Metzner, B, Hübel, K, Silling, G, Hentrich, M, Franke, D, Schwerdtfeger, R, Freund, M, Sezer, O, Giagounidis, A, Ehninger, G, Grimminger, W, Engert, A, Schlimok, G, Scheid, C, Hellmann, P, Heinisch, H, Einsele, H, Hinke, A & Emmerich, B 2011, 'Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.', BLOOD, Jg. 117, Nr. 7, 7, S. 2121-2128. <http://www.ncbi.nlm.nih.gov/pubmed/21163927?dopt=Citation>

APA

Straka, C., Sandherr, M., Salwender, H., Wandt, H., Metzner, B., Hübel, K., Silling, G., Hentrich, M., Franke, D., Schwerdtfeger, R., Freund, M., Sezer, O., Giagounidis, A., Ehninger, G., Grimminger, W., Engert, A., Schlimok, G., Scheid, C., Hellmann, P., ... Emmerich, B. (2011). Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. BLOOD, 117(7), 2121-2128. [7]. http://www.ncbi.nlm.nih.gov/pubmed/21163927?dopt=Citation

Vancouver

Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K et al. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. BLOOD. 2011;117(7):2121-2128. 7.

Bibtex

@article{d791a2df737040899301f5310456f41e,
title = "Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.",
abstract = "The individual risk of infection and requirements for medical treatment after high-dose chemotherapy have been unpredictable. In this prospective, multicenter, open-label study we investigated the potential of granulocyte colony-stimulating factor (G-CSF) responsiveness as a predictor. A total of 168 patients with multiple myeloma or lymphoma received a single dose of subcutaneous G-CSF (lenograstim, 263 ?g) after high-dose chemotherapy. Highly variable leukocyte peaks were measured and grouped as low (quartile 1; leukocytes 100-10 100/?L), medium (quartile 2; leukocytes > 10 100-18 300/?L), and high (quartiles 3/4; leukocytes > 18 300-44 800/?L). G-CSF responsiveness (low vs medium vs high) was inversely correlated with febrile neutropenia (77% vs 60% vs 48%; P = .0037); the rate of infection, including fever of unknown origin (91% vs 67% vs 54%; P <.0001); days with intravenous antibiotics (9 vs 6 vs 5; P <.0001); and antifungal therapy (P = .042). In multivariate analysis, G-CSF responsiveness remained the only factor significantly associated with infection (P = .016). In addition, G-CSF responsiveness was inversely correlated with grade 3/4 oral mucositis (67% vs 33% vs 23%; P <.0001). G-CSF responsiveness appears as a signature of the myeloid marrow reserve predicting defense against neutropenic infection after intensive chemotherapy. This study is registered at http://www.clinicaltrials.gov as NCT01085058.",
author = "Christian Straka and Michael Sandherr and Hans Salwender and Hannes Wandt and Bernd Metzner and Kai H{\"u}bel and Gerda Silling and Marcus Hentrich and Daniel Franke and Rainer Schwerdtfeger and Mathias Freund and Orhan Sezer and Alexander Giagounidis and Gerhard Ehninger and Wolfgang Grimminger and Andreas Engert and G{\"u}nter Schlimok and Christof Scheid and Peter Hellmann and Harald Heinisch and Hermann Einsele and Axel Hinke and Bertold Emmerich",
year = "2011",
language = "English",
volume = "117",
pages = "2121--2128",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

RIS

TY - JOUR

T1 - Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.

AU - Straka, Christian

AU - Sandherr, Michael

AU - Salwender, Hans

AU - Wandt, Hannes

AU - Metzner, Bernd

AU - Hübel, Kai

AU - Silling, Gerda

AU - Hentrich, Marcus

AU - Franke, Daniel

AU - Schwerdtfeger, Rainer

AU - Freund, Mathias

AU - Sezer, Orhan

AU - Giagounidis, Alexander

AU - Ehninger, Gerhard

AU - Grimminger, Wolfgang

AU - Engert, Andreas

AU - Schlimok, Günter

AU - Scheid, Christof

AU - Hellmann, Peter

AU - Heinisch, Harald

AU - Einsele, Hermann

AU - Hinke, Axel

AU - Emmerich, Bertold

PY - 2011

Y1 - 2011

N2 - The individual risk of infection and requirements for medical treatment after high-dose chemotherapy have been unpredictable. In this prospective, multicenter, open-label study we investigated the potential of granulocyte colony-stimulating factor (G-CSF) responsiveness as a predictor. A total of 168 patients with multiple myeloma or lymphoma received a single dose of subcutaneous G-CSF (lenograstim, 263 ?g) after high-dose chemotherapy. Highly variable leukocyte peaks were measured and grouped as low (quartile 1; leukocytes 100-10 100/?L), medium (quartile 2; leukocytes > 10 100-18 300/?L), and high (quartiles 3/4; leukocytes > 18 300-44 800/?L). G-CSF responsiveness (low vs medium vs high) was inversely correlated with febrile neutropenia (77% vs 60% vs 48%; P = .0037); the rate of infection, including fever of unknown origin (91% vs 67% vs 54%; P <.0001); days with intravenous antibiotics (9 vs 6 vs 5; P <.0001); and antifungal therapy (P = .042). In multivariate analysis, G-CSF responsiveness remained the only factor significantly associated with infection (P = .016). In addition, G-CSF responsiveness was inversely correlated with grade 3/4 oral mucositis (67% vs 33% vs 23%; P <.0001). G-CSF responsiveness appears as a signature of the myeloid marrow reserve predicting defense against neutropenic infection after intensive chemotherapy. This study is registered at http://www.clinicaltrials.gov as NCT01085058.

AB - The individual risk of infection and requirements for medical treatment after high-dose chemotherapy have been unpredictable. In this prospective, multicenter, open-label study we investigated the potential of granulocyte colony-stimulating factor (G-CSF) responsiveness as a predictor. A total of 168 patients with multiple myeloma or lymphoma received a single dose of subcutaneous G-CSF (lenograstim, 263 ?g) after high-dose chemotherapy. Highly variable leukocyte peaks were measured and grouped as low (quartile 1; leukocytes 100-10 100/?L), medium (quartile 2; leukocytes > 10 100-18 300/?L), and high (quartiles 3/4; leukocytes > 18 300-44 800/?L). G-CSF responsiveness (low vs medium vs high) was inversely correlated with febrile neutropenia (77% vs 60% vs 48%; P = .0037); the rate of infection, including fever of unknown origin (91% vs 67% vs 54%; P <.0001); days with intravenous antibiotics (9 vs 6 vs 5; P <.0001); and antifungal therapy (P = .042). In multivariate analysis, G-CSF responsiveness remained the only factor significantly associated with infection (P = .016). In addition, G-CSF responsiveness was inversely correlated with grade 3/4 oral mucositis (67% vs 33% vs 23%; P <.0001). G-CSF responsiveness appears as a signature of the myeloid marrow reserve predicting defense against neutropenic infection after intensive chemotherapy. This study is registered at http://www.clinicaltrials.gov as NCT01085058.

M3 - SCORING: Journal article

VL - 117

SP - 2121

EP - 2128

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 7

M1 - 7

ER -